Pfizer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PFIZER
PFIZER has one hundred and ninety-seven approved drugs.
There are fifty US patents protecting PFIZER drugs. There is one tentative approval on PFIZER drugs.
Summary for Pfizer
| US Patents: | 50 |
| Tradenames: | 161 |
| Ingredients: | 131 |
| NDAs: | 197 |
| Patent Litigation for Pfizer: | See patent lawsuits for Pfizer |
| PTAB Cases with Pfizer as petitioner: | See PTAB cases with Pfizer as petitioner |
Drugs and US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | PAXLOVID (COPACKAGED) | nirmatrelvir; ritonavir | TABLET;ORAL | 217188-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Pfizer | MERREM IV | meropenem | INJECTABLE;INJECTION | 050706-001 | Jun 21, 1996 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-001 | Mar 7, 2024 | RX | Yes | No | 8,420,650 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-003 | Jun 27, 1996 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pfizer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | DIFLUCAN | fluconazole | FOR SUSPENSION;ORAL | 020090-001 | Dec 23, 1993 | 4,416,682 | ⤷ Start Trial |
| Pfizer | TZ-3 | tioconazole | CREAM;TOPICAL | 018682-001 | Feb 18, 1983 | 4,661,493 | ⤷ Start Trial |
| Pfizer | COVERA-HS | verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020552-002 | Feb 26, 1996 | 5,785,994 | ⤷ Start Trial |
| Pfizer | GLUCOTROL | glipizide | TABLET;ORAL | 017783-002 | May 8, 1984 | 3,669,966 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PFIZER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 11 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Capsules | 20 mg, 40 mg, 60 mg and 80 mg | ➤ Subscribe | 2005-02-07 |
| ➤ Subscribe | Capsules | 75 mg, 100 mg and 125 mg | ➤ Subscribe | 2019-02-04 |
| ➤ Subscribe | Capsules | 0.125 mg, 0.25 mg, and 0.5 mg | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2005-12-21 |
| ➤ Subscribe | Injection | 2 mg/mL, 300 mL bag | ➤ Subscribe | 2009-09-01 |
| ➤ Subscribe | Tablets | 1 g | ➤ Subscribe | 2005-08-23 |
| ➤ Subscribe | Delayed-release Tablets | 75 mg/0.2 mg | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Extended-release Tablets | 4 mg and 8 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Injection | 20 mg/mL, 2 mL and 5 mL vials | ➤ Subscribe | 2004-07-26 |
| ➤ Subscribe | Capsules | 5 mg and 10 mg | ➤ Subscribe | 2005-06-21 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Oral Suspension | 100 mg/5 mL | ➤ Subscribe | 2009-08-03 |
| ➤ Subscribe | Injection | 2 mg/mL, 100 mL bag | ➤ Subscribe | 2009-12-29 |
| ➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg/0.2 mg | ➤ Subscribe | 2009-06-29 |
International Patents for Pfizer Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Singapore | 10201809895Y | ⤷ Start Trial |
| Mexico | 2014009544 | ⤷ Start Trial |
| South Africa | 202108834 | ⤷ Start Trial |
| New Zealand | 737391 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pfizer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2767537 | SPC/GB19/070 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: TALAZOPARIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS THE TOSYLATE SALT; REGISTERED: UK EU/1/19/1377 (NI) 20190624; UK PLGB00057-1672 20190624; UK PLGB00057-1673 20190624 |
| 1667986 | 28/2013 | Austria | ⤷ Start Trial | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 |
| 2822953 | C20190036 00302 | Estonia | ⤷ Start Trial | PRODUCT NAME: LORLATINIIB;REG NO/DATE: EU/1/19/1355 08.05.2019 |
| 2488512 | CA 2022 00036 | Denmark | ⤷ Start Trial | PRODUCT NAME: RIMEGEPANT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/22/1645 20220426 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
